## ALGN: Align Technology, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.5% in lower entry zone (3.0-6.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (2.0%) confirms momentum alignment. Strong momentum (+1.3% 5-day acceleration). Outperforming sector by 5.8%. Caution: overbought RSI (73).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($147.41)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Align Technology Showcases Digital Dentistry Innovations at Greater New York Dental Meeting 2025**
- Source: Morningstar | 20251203T205500 | Bullish | Relevance: 100%
- Align Technology (NASDAQ: ALGN) showcased its latest digital dentistry innovations at the Greater New York Dental Meeting 2025, highlighting advancements in its Align™ Digital Platform. Key innovations presented included the iTero Lumina™ scanner, Align™ Oral Health Suite, Invisalign Smile Architect™, iTero™ Design Suite, and ClinCheck® Signature experience, designed to enhance clinical outcomes and patient treatment. The company also sponsored clinical education sessions led by industry experts, emphasizing its commitment to advancing digital dentistry.

**2. Assessing Align Technology (ALGN) Valuation After Invisalign Mandibular Launch and 6% Share Price Jump**
- Source: Simply Wall Street | 20251203T120305 | Somewhat-Bullish | Relevance: 100%
-  Align Technology (ALGN) saw a 6% share price jump after launching its Invisalign System with mandibular advancement in the Philippines. Despite a recent uptick, the stock is still down significantly year-to-date, leading to a debate about whether it is undervalued. The company's valuation narrative suggests it is about 16% undervalued, driven by expanding clinical indications and increased adoption by general practitioner dentists.

**3. Align Technology Showcases Digital Dentistry Innovations at Greater New York Dental Meeting 2025**
- Source: Business Wire | 20251204T090919 | Bullish | Relevance: 99%
- Align Technology highlighted its latest innovations in digital dentistry at the Greater New York Dental Meeting 2025, showcasing advancements across its Align™ Digital Platform. Key features included the iTero Lumina™ scanner, Align™ Oral Health Suite, Invisalign Smile Architect™, iTero™ Design Suite, and ClinCheck® Signature experience, alongside educational sessions from industry experts. The company emphasized how these innovations enhance treatment planning, practice workflows, and patient experiences for dental professionals.

**4. Align Technology (NASDAQ: ALGN) spotlights iTero, exocad, Invisalign at GNYDM 2025**
- Source: Stock Titan | 20251203T205500 | Bullish | Relevance: 99%
- Align Technology showcased its latest digital dentistry innovations at the Greater New York Dental Meeting (GNYDM) 2025, highlighting advancements across its Align Digital Platform, including the Invisalign system, iTero intraoral scanners, and exocad CAD/CAM software. The company featured new products like the iTero Lumina scanner and Invisalign Smile Architect, alongside educational sessions for dental professionals. These innovations aim to enhance treatment planning, practice efficiency, and patient outcomes for dental practices worldwide.

**5. Align Technology Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T171800 | Bullish | Relevance: 99%
- Align Technology Inc. (ALGN) saw its stock advance by 2.70% to $155.00 on Wednesday. This strong performance occurred during a favorable trading session where the S&P 500 Index and Dow Jones Industrial Average also rose. This marks the second consecutive day of gains for Align Technology Inc.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $170 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (+0.7%)
- Blackrock Inc.: 6.9% (-3.4%)
- Ninety One UK Ltd: 6.3% (+136.6%)
- Capital Internationa: 4.2% (+88.6%)
- State Street Corpora: 4.0% (-1.3%)

### Key Risks

1. High beta (1.86) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +1.3% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.76 indicates undervaluation relative to growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $11.5B |
| Beta | 1.86 |
| 52W Range | $122.00 - $246.19 |
| Short Interest | 5.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.76 |
| Forward P/E | 14.4 |
| Current P/E | 15.4 |
| YoY Growth | 7.5% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 2.1% to 3.5% (+1.3% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 2.0% confirms short-term momentum alignment. Outperforming sector by 5.8pp, stock-specific strength. Below SMA200 (0.98x), long-term trend not supportive. MACD histogram positive (1.73), confirming momentum. RSI overbought at 73, risk of mean reversion.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.49% (CS: 83) | Strong |
| RSI_14 | 73.3 | Overbought |
| MACD Histogram | 1.73 | Bullish |
| vs SMA20 | 1.099x | Above |
| vs SMA50 | 1.151x | Above |
| vs SMA200 | 0.980x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $157.21
- **Stop Loss:** $147.41 (6.2% risk)
- **Target:** $171.91 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $8,017.71
- **Portfolio %:** 8.02%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-04 (Est: $2.96)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.41 | $2.61 | +8.4% |
| 2025Q2 | $2.57 | $2.49 | -3.3% |
| 2025Q1 | $1.99 | $2.13 | +7.1% |
| 2024Q4 | $2.45 | $2.44 | -0.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*